Abstract
Treatment for major depressive disorder usually moves through phases, starting with getting well and then turning to staying well. Guidelines from England and Canada match the first treatment to how severe the depression is and to what the person prefers, and the choice is made together with a clinician. Continuing an antidepressant after recovery, and some talking therapies, lower the chance that depression comes back. Depression that is severe or has not responded to earlier treatment has further options, including electroconvulsive therapy and added medicines. Some questions are still uncertain, such as how much published trials overstate the benefit of treatment and how often depression lifts without it.
Keywords: major depressive disorder, relapse prevention, maintenance treatment, antidepressants, psychotherapy
Get Help Now
Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.
- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).
This guide describes what published clinical guidelines and research reviews say about treating major depressive disorder. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.
How Treatment Unfolds
The Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline describes depression care for adults as collaborative, personalized and systematic, with decisions shared between the person and the clinician (Lam et al., 2024). It divides care into an acute phase, which usually lasts about 8 to 16 weeks, and a later phase of continuing treatment that aims to keep depression from returning (Lam et al., 2024). The acute phase aims at safety and at remission, and the guideline defines a response as symptoms improving by half or more (Lam et al., 2024). CANMAT also describes measurement-based care, which means tracking symptoms over time with rating scales such as the PHQ-9 questionnaire (Lam et al., 2024). In the guideline, a drop of less than 20% within 2 to 4 weeks of starting an antidepressant counts as a lack of early improvement (Lam et al., 2024). This lack of early improvement is strongly linked with not responding later (Lam et al., 2024).
In England, the National Institute for Health and Care Excellence (NICE) lets people choose, together with their clinician, from several first-line options that fit their needs and wishes (National Institute for Health and Care Excellence, 2022). In the United States, the National Institute of Mental Health (NIMH) notes that depression is treated with talking therapy, medicine or both (National Institute of Mental Health, 2024). It also notes that finding the best treatment may take trial and error (National Institute of Mental Health, 2024). A wider guide to depression treatment covers each type of therapy and medicine in more detail.
How Severity Shapes the Choice
NICE sorts depression into less severe and more severe groups, with a score of 16 on the PHQ-9 as the dividing line (National Institute for Health and Care Excellence, 2022). For less severe depression, NICE lists guided self-help first, based on cognitive behavioural therapy (CBT) or behavioural activation (National Institute for Health and Care Excellence, 2022). NICE advises against routinely offering an antidepressant as the first step (National Institute for Health and Care Excellence, 2022). The exception is when an antidepressant is the person's informed preference (National Institute for Health and Care Excellence, 2022). For more severe depression, it lists CBT combined with an antidepressant first (National Institute for Health and Care Excellence, 2022). The National Health Service (NHS) in the United Kingdom also lists different treatments for mild depression than for moderate or severe depression (National Health Service, 2023).
Researchers disagree about whether antidepressants help more when depression is more severe. One pooled analysis used patient data from 6 studies, with 718 adult outpatients (Fournier et al., 2010). The gain from medicine over a placebo (a dummy treatment) grew with severity (Fournier et al., 2010). For people scoring below 23 on the Hamilton scale, the gain was smaller than the usual threshold for a small effect (Fournier et al., 2010). A later analysis of 2,464 patients from Japanese trials found no significant link between severity and benefit, which suggests a similar gain at mild, moderate and severe levels (Furukawa et al., 2018). That analysis had full patient data from only six of eleven eligible trials (Furukawa et al., 2018).
Staying Well After Recovery
NICE guidance describes a usual course of 6 months or more on an antidepressant, counting the time after symptoms remit (National Institute for Health and Care Excellence, 2022). This period comes with regular reviews (National Institute for Health and Care Excellence, 2022). CANMAT recommends continuing antidepressants for 6 to 12 months after remission, and for 2 years or more in people with risk factors for recurrence (Lam et al., 2024). NICE names several features that may increase the likelihood of relapse (National Institute for Health and Care Excellence, 2022). They include repeated past episodes, an incomplete response to earlier treatment, and severe depression (National Institute for Health and Care Excellence, 2022). Avoidance or rumination, which means going over the same worries again and again, also counts (National Institute for Health and Care Excellence, 2022). When an antidepressant is stopped, NICE advises talking with the prescriber and usually reducing the dose in stages (National Institute for Health and Care Excellence, 2022). NICE notes that withdrawal symptoms usually go away within 1 to 2 weeks (National Institute for Health and Care Excellence, 2022). They can sometimes last several weeks or, occasionally, several months (National Institute for Health and Care Excellence, 2022).
One UK trial followed 478 adults from 150 general practices who had been taking antidepressants and felt well enough to consider stopping (Lewis et al., 2021). All had had at least two episodes or had taken antidepressants for 2 years or more (Lewis et al., 2021). About half kept their medicine, while half tapered onto a matching placebo without knowing it (Lewis et al., 2021). Over 52 weeks, 39% of those who continued relapsed, compared with 56% of those who stopped (Lewis et al., 2021). The stopping group also had more depression, anxiety and withdrawal symptoms, although fewer people in that group kept to their assigned pills (Lewis et al., 2021).
Talking therapy can also guard against relapse. For people with recurrent depression, a review of patient data from 9 studies with 1,258 people found that mindfulness-based cognitive therapy (MBCT) lowered relapse risk over 60 weeks (Kuyken et al., 2016). The risk was lower than with care that did not include MBCT, and comparisons with other active treatments also suggested a lower risk (Kuyken et al., 2016). For people at higher risk of relapse, NICE lists group CBT or MBCT as ways to prevent relapse (National Institute for Health and Care Excellence, 2022). CANMAT reports that talking therapy appears to be as effective as antidepressants at preventing recurrence, and that ongoing antidepressants can cut relapse by about half compared with placebo (Lam et al., 2024).
When Depression Is Severe
For more severe depression, NICE lists CBT with an antidepressant, and the therapist sessions give support while the medicine takes time to work (National Institute for Health and Care Excellence, 2022). If an antidepressant has had no or a limited response, NICE lists adding a second medicine such as lithium or an antipsychotic (National Institute for Health and Care Excellence, 2022). NICE describes this step for people who want to try combining medicines and accept a possible increase in side effects, and advises considering referral to, or advice from, a specialist (National Institute for Health and Care Excellence, 2022). The NHS describes referral to a specialist or a mental health team for severe depression, and brain stimulation when severe depression has not responded to other treatment (National Health Service, 2023).
NIMH lists electroconvulsive therapy (ECT) among brain stimulation therapies, which are used less often than talking therapy or medicine (National Institute of Mental Health, 2024). CANMAT reports ECT response rates of about 65% to 75%, and finds ECT more effective than other noninvasive stimulation methods for difficult-to-treat depression, although it has more side effects (Lam et al., 2024). It also notes that depression returns in 60% to 80% of people by 6 months after ECT (Lam et al., 2024). For this reason, it advises a maintenance treatment afterwards (Lam et al., 2024). It reports response rates of about 40% to 50% for repetitive transcranial magnetic stimulation (rTMS) in difficult-to-treat depression, with the strength of evidence depending on how it is given (Lam et al., 2024). A 2003 review found that real ECT worked better than simulated ECT in the short term, and probably better than drug treatment (UK ECT Review Group, 2003).
On memory and thinking, a review of 84 studies with 2,981 patients found that problems after ECT appeared mainly in the first 3 days (Semkovska & McLoughlin, 2010). After about 15 days, test scores were back to pre-treatment levels, and some had improved (Semkovska & McLoughlin, 2010). The authors noted that memory for past events had not been checked with standard tests (Semkovska & McLoughlin, 2010).
Adding an antipsychotic to an antidepressant was tested in 14 short placebo-controlled trials of adults with treatment-resistant depression, meaning depression that earlier treatment had not relieved (Spielmans et al., 2013). The added medicines gave a small to moderate benefit on depression, but mostly little or no benefit on quality of life or daily functioning (Spielmans et al., 2013). Harms included weight gain, restlessness and sleepiness, every trial was funded at least in part by a drug maker, and the authors urged caution (Spielmans et al., 2013).
Exercise and Everyday Approaches
A network review of 218 studies with 14,170 participants found that exercise eased depression, with moderate effects (Noetel et al., 2024). Walking or jogging, yoga and strength training did best, vigorous exercise beat light exercise, and the effects were similar in size to those of CBT (Noetel et al., 2024). The authors judged exercise effective (Noetel et al., 2024). However, only one study had a low risk of bias (Noetel et al., 2024). For that reason, they gave walking or jogging a low confidence rating and other types a very low one (Noetel et al., 2024). NICE includes a group exercise programme among its treatments, and lists adding group exercise as an option when antidepressant medicine alone has not helped (National Institute for Health and Care Excellence, 2022). CANMAT recommends supervised exercise as a first-line treatment for mild depression (Lam et al., 2024). It notes, though, that the evidence for exercise, complementary medicine and digital tools is weaker than for medicine and talking therapy (Lam et al., 2024).
What Is Still Uncertain
Some researchers question how far the evidence can be trusted. A comparison of 74 antidepressant trials registered with the US Food and Drug Administration (FDA) found that 94% of published trials looked positive, while the FDA judged only 51% positive (Turner et al., 2008). Overall, the published studies made the drugs look about 32% more effective (Turner et al., 2008). A reanalysis of 522 trials found bias and a small average effect, about 2 points on a 52-point scale, so no firm conclusion about benefit was possible (Munkholm et al., 2019). Talking therapy shows a similar pattern: about a quarter of funded US therapy trials went unpublished, and the published ones overstated the effect, although the authors still judged therapy effective (Driessen et al., 2015). On the other side, a review of 522 trials with 116,477 participants found all 21 antidepressants better than placebo, with certainty ranging from moderate to very low (Cipriani et al., 2018). Another review of 101 studies with 11,910 patients found therapy and medicine about equal, and the two combined better than either alone (Cuijpers et al., 2020).
A second open question is what happens without treatment. A review of 19 studies estimated how often untreated depression remits (Whiteford et al., 2013). Among adults seen in primary care, about 23% of untreated cases remitted by 3 months, 32% by 6 months and 53% by 12 months (Whiteford et al., 2013). Wait-listed samples were less likely to remit (Whiteford et al., 2013). The data came from wait-list and primary-care samples, which may over-represent milder cases, and the results may not apply to more severe depression (Whiteford et al., 2013). For mild depression, the NHS notes that a GP may suggest a short wait to see whether it lifts without treatment, with a check-up after 2 to 4 weeks (National Health Service, 2023).
Learn More
More detail is in the full article on major depressive disorder and the guide to depression treatment. There is also a guide to major depressive disorder symptoms.
Frequently Asked Questions
How long does treatment for major depressive disorder usually last?
CANMAT describes an acute phase of about 8 to 16 weeks, followed by 6 to 12 months of continued treatment after remission (Lam et al., 2024).
What happens when a person stops an antidepressant after recovering?
In a UK primary care trial of adults who felt well enough to stop, 56% of those assigned to stop relapsed within 52 weeks, against 39% of those assigned to continue (Lewis et al., 2021). NICE advises that stopping is agreed with the person and done by slowly reducing the dose (National Institute for Health and Care Excellence, 2022).
Are withdrawal symptoms a sign that depression has returned?
NICE advises monitoring for both withdrawal symptoms and the return of depression while the dose is reduced, and notes that withdrawal symptoms usually go away within 1 to 2 weeks but can sometimes last longer (National Institute for Health and Care Excellence, 2022).
Can therapy help keep depression from coming back?
For people with recurrent depression, mindfulness-based cognitive therapy lowered the risk of relapse over 60 weeks in a review of 9 studies (Kuyken et al., 2016).
Do antidepressants help with mild depression?
For mild depression the NHS lists waiting to see if it improves, guided self-help, exercise, and talking therapy if it is not improving, and it says antidepressants help most, though not all, people with moderate or severe depression (National Health Service, 2023).
Can exercise treat depression?
A large review found moderate effects of exercise on depression, with walking or jogging, yoga and strength training doing best, but the authors gave walking or jogging a low confidence rating and other types a very low one (Noetel et al., 2024).
How This Article Was Prepared
This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests mainly on secondary sources: two clinical guidelines, 13 reviews of the research and two pages from public health agencies, with one single study cited where no review covered the point.
- Included: 18 sources, each confirmed against the publisher's or indexer's own record. Eight read in full text and 10 from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 15 references carry a PubMed ID and nine a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 15 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: two from the 2000s, nine from the 2010s and seven from 2020 or later. - Checked against sources: each of the 80 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over four passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.
See our Editorial Policy for the full method.
References
Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7 PMID: 29477251 · PMCID: PMC5889788
Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92-107. https://doi.org/10.1002/wps.20701 PMID: 31922679 · PMCID: PMC6953550
Driessen, E., Hollon, S. D., Bockting, C. L. H., Cuijpers, P., & Turner, E. H. (2015). Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? A systematic review and meta-analysis of US National Institutes of Health-funded trials. PLoS ONE, 10(9), e0137864. https://doi.org/10.1371/journal.pone.0137864 PMID: 26422604 · PMCID: PMC4589340
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303(1), 47-53. https://doi.org/10.1001/jama.2009.1943 PMID: 20051569 · PMCID: PMC3712503
Furukawa, T. A., Maruo, K., Noma, H., Tanaka, S., Imai, H., Shinohara, K., Ikeda, K., Yamawaki, S., Levine, S. Z., Goldberg, Y., Leucht, S., & Cipriani, A. (2018). Initial severity of major depression and efficacy of new generation antidepressants: Individual participant data meta-analysis. Acta Psychiatrica Scandinavica, 137(6), 450-458. https://doi.org/10.1111/acps.12886 PMID: 29611870
Kuyken, W., Warren, F. C., Taylor, R. S., Whalley, B., Crane, C., Bondolfi, G., Hayes, R., Huijbers, M., Ma, H., Schweizer, S., Segal, Z., Speckens, A., Teasdale, J. D., Van Heeringen, K., Williams, M., Byford, S., Byng, R., & Dalgleish, T. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry, 73(6), 565-574. https://doi.org/10.1001/jamapsychiatry.2016.0076 PMID: 27119968 · PMCID: PMC6640038
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., Do, A., Frey, B. N., Giacobbe, P., Gratzer, D., Grigoriadis, S., Habert, J., Husain, M. I., Ismail, Z., McGirr, A., . . . Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384 PMID: 38711351 · PMCID: PMC11351064
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., Hunt, A., Pervin, J., & Lewis, G. (2021). Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine, 385(14), 1257-1267. https://doi.org/10.1056/NEJMoa2106356 PMID: 34587384
Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019). Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open, 9(6), e024886. https://doi.org/10.1136/bmjopen-2018-024886 PMID: 31248914 · PMCID: PMC6597641
National Health Service. (2023, July 5). Treatment - Depression in adults. NHS. https://www.nhs.uk/mental-health/conditions/depression-in-adults/treatment/
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations
National Institute of Mental Health. (2024). Depression (NIH Publication No. 24-MH-8079). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/depression
Noetel, M., Sanders, T., Gallardo-Gómez, D., Taylor, P., del Pozo Cruz, B., van den Hoek, D., Smith, J. J., Mahoney, J., Spathis, J., Moresi, M., Pagano, R., Pagano, L., Vasconcellos, R., Arnott, H., Varley, B., Parker, P., Biddle, S., & Lonsdale, C. (2024). Effect of exercise for depression: Systematic review and network meta-analysis of randomised controlled trials. BMJ, 384, e075847. https://doi.org/10.1136/bmj-2023-075847 PMID: 38355154 · PMCID: PMC10870815
Semkovska, M., & McLoughlin, D. M. (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biological Psychiatry, 68(6), 568-577. https://doi.org/10.1016/j.biopsych.2010.06.009 PMID: 20673880
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Medicine, 10(3), e1001403. https://doi.org/10.1371/journal.pmed.1001403 PMID: 23554581 · PMCID: PMC3595214
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252-260. https://doi.org/10.1056/NEJMsa065779 PMID: 18199864
UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. The Lancet, 361(9360), 799-808. https://doi.org/10.1016/S0140-6736(03)12705-5 PMID: 12642045
Whiteford, H. A., Harris, M. G., McKeon, G., Baxter, A., Pennell, C., Barendregt, J. J., & Wang, J. (2013). Estimating remission from untreated major depression: A systematic review and meta-analysis. Psychological Medicine, 43(8), 1569-1585. https://doi.org/10.1017/S0033291712001717 PMID: 22883473